Phosphoinositide 3-kinase/ Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia

Leukemia

Volumn 20, Issue 6, 2006, Pages 911-928

  Martelli, A M ^a,b   Nyakern M ^a   Tabellini, G ^c   Bortul, R ^d   Tazzari, P L ^e   Evangelisti, C ^a   Cocco, L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

3 phosphorylated inositol lipids; Apoptosis; Drug resistance; Signal transduction networks; Targeted molecular therapy

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 7 HYDROXYSTAUROSPORINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ENZYME INHIBITOR; ERLOTINIB; ETOPOSIDE; FLT3 LIGAND; GEFITINIB; HISTONE ACETYLTRANSFERASE INHIBITOR; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN P110; PROTEIN TYROSINE KINASE INHIBITOR; PX 866; RAPAMYCIN; RAS PROTEIN; RECEPTOR BLOCKING AGENT; RETINOIC ACID; SOMATOMEDIN C RECEPTOR BLOCKING AGENT; SORAFENIB; STEM CELL FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; WORTMANNIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE REGULATION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG HALF LIFE; DRUG SENSITIVITY; DRUG SOLUBILITY; ENZYME ACTIVATION; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 33744457653     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404245     Document Type: Article

References (250)

1. Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004; 50: 197-222.
2. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004; 5: 443-450.
3. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-1163.
4. Lowenberg B, Downing JR, Barnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
5. Grimwade D, Enver T. Acute promyelocytic leukemia: Where does it stem from? Leukemia 2004; 18: 375-384.
6. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106: 4086-4092.
7. Warner JK, Wang JC, Takenaka K, Doulatov S, McKenzie JL, Harrington L et al. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia 2005; 19: 1794-1805.
8. Sambani C, La Starza R, Roumier C, Crescenzi B, Stavropoulou C, Katsarou O et al. Partial duplication of the MLL oncogene in patients with aggressive acute myeloid leukemia. Haematologica 2004; 89: 403-407.
9. Tonks A, Tonks AJ, Pearn L, Pearce L, Hoy T, Couzens S et al. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 2004; 18: 1238-1245.
10. Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 2005; 19: 1361-1366.
11. Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004; 18: 466-475.
12. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: A meta-analysis. Leukemia 2005; 19: 1345-1349.
13. Cammenga J. Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML. Leukemia 2005; 19: 1719-1728.
14. Moore MA. Converging pathways in leukemogenesis and stem cell self-renewal. Exp Hematol 2005; 33: 719-737.
15. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKT ion on multiple fronts. Trends Biochem Sci 2004; 29: 233-242.
16. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/ AKT - a major therapeutic target. Biochim Biophys Acta 2004; 1697: 3-16.
17. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29-86.
18. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 2004; 9: 667-676.
19. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9: 59-71.
20. Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 2005; 10: 975-987.
21. Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T. Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: Direct evidence of PI3K activation. Leukemia 2004; 18: 1438-1440.
22. Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: Its significance as a prognostic variable. Leukemia 2003; 17: 995-997.
23. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102: 972-980.
24. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 2004; 18: 267-275.
25. Stauffer F, Holzer P, Garcia-Echeverria C. Blocking the PI3K/PKB pathway in tumor cells. Curr Med Chem Anti-Canc Agents 2005; 5: 449-462.
26. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: Insights from gene-targeted mice. Trends Biochem Sci 2005; 30: 194-204.
27. Anderson KE, Jackson SP. Class I phosphoinositide 3-kinases. Int J Biochem Cell Biol 2003; 35: 1028-1033.
28. Stephens L, Williams R, Hawkins P. Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol 2005; 5: 357-365.
29. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
30. Wymann MP, Bjorklof K, Calvez R, Finan P, Thomast M, Trifilieff A et al. Phosphoinositide 3-kinase gamma: A key modulator in inflammation and allergy. Biochem Soc Trans 2003; 31: 275-280.
31. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: Size matters. Oncogene 2003; 22: 8983-8998.
32. Steelman LS, Bertrand FE, McCubrey JA. The complexity of PTEN: Mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets 2004; 8: 537-550.
33. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw III EB et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β). Science 2001; 292: 1728-1731.
34. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001; 15: 2203-2208.
35. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS et al. Role for Akt3/protein kinase Bγ in attainment of normal brain size. Mol Cell Biol 2005; 25: 1869-1878.
36. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101.
37. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F et al. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 2005; 12: 668-677.
38. Ye K. PIKE/nuclear PI 3-kinase signaling in preventing programmed cell death. J Cell Biochem 2005; 96: 463-472.
39. Du K, Tsichlis PN. Regulation of the Akt kinase by interacting proteins. Oncogene 2005; 24: 7401-7409.
40. Pearl LH. Hsp90 and Cdc37 - a chaperone cancer conspiracy. Curr Opin Genet Dev 2005; 15: 55-61.
41. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002; 5: 234-248.
42. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7: 97-110.
43. Plo I, Bettaieb A, Payrastre B, Mansat-De Mas V, Bordier C, Rousse A et al. The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines. FEBS Lett 1999; 452: 150-154.
44. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
45. Zauli G, Sancilio S, Cataldi A, Sabatini N, Bosco D, Di Pietro R. PI-3K/ Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment. J Cell Physiol 2005; 202: 900-911.
46. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189-218.
47. Backers K, Blero D, Paternotte N, Zhang J, Erneux C. The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases. Adv Enzyme Regul 2003; 43: 15-28.
48. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-2963.
49. Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia BP et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 2002; 21: 5289-5300.
50. Janssens V, Goris J, Van Hoof C. PP2A: The expected tumor suppressor. Curr Opin Genet Dev 2005; 15: 34-41.
51. Borgatti P, Martelli AM, Tabellini G, Bellacosa A, Capitani S, Neri LM. Threonine 308 phosphorylated form of Akt translocates to the nucleus of PC12 cells under nerve growth factor stimulation and associates with the nuclear matrix protein nucleolin. J Cell Physiol 2003; 196: 79-88.
52. Liu W, Akhand AA, Takeda K, Kawamoto Y, Itoigawa M, Kato M et al. Protein phosphatase 2A-linked and -unlinked caspase-dependent pathways for downregulation of Akt kinase triggered by 4-hydroxynonenal. Cell Death Differ 2003; 10: 772-781.
53. Gao T, Furnari F, Newton AC. PHLPP: A phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005; 18: 13-24.
54. Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwable J et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 2005; 65: 9643-9650.
55. Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005; 19: 586-594.
56. Kornblau SM, Womble M, Cade JS, Lemker E, Qiu YH. Comparative analysis of the effects of sample source and test methodology on the assessment of protein expression in acute myelogenous leukemia. Leukemia 2005; 19: 1550-1557.
57. Tazzari PL, Cappellini A, Grafone T, Mantovani I, Ricci F, Billi AM et al. Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry. Br J Haematol 2004; 126: 675-681.
58. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga E. Constitutive NF-κB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004; 18: 103-112.
59. Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Naoe T. Different antiapoptotic pathways between wild-type and mutated FLT3: Insights into therapeutic targets in leukemia. Blood 2003; 102: 2969-2975.
60. Scheijen B, Ngo HT, Kang H, Griffin JD. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 2004; 23: 3338-3349.
61. Choudhary C, Schwable J, Brandts C, Tickenbrock L, Sargin B, Kindler T et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 2005; 106: 265-273.
62. Schwable J, Choudhary C, Thiede C, Tickenbrock L, Sargin B, Steur C et al. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Blood 2005; 105: 2107-2114.
63. Noguera NI, Ammatuna E, Zangrilli D, Lavorgna S, Divona M, Buccisano F et al. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 2005; 19: 1479-1482.
64. Naoe T, Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci 2004; 61: 2932-2938.
65. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol 2005; 23: 6285-6295.
66. Roskoski Jr R. Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor. Biochem Biophys Res Commun 2005; 338: 1307-1315.
67. Kohl TM, Schnittger S, Ellwart JW, Hiddemann W, Spiekermann K. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2005; 105: 3319-3321.
68. Ning ZQ, Li J, McGuinness M, Arceci RJ. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity. Oncogene 2001; 20: 4528-4536.
69. Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: A t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 2005; 46: 247-255.
70. Beghini A, Bellini M, Magnani I, Colapietro P, Cairoli R, Morra E et al. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade. Exp Hematol 2005; 33: 682-688.
71. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005; 106: 1063-1066.
72. Sawyer C, Sturge J, Bennett DC, O'Hare MJ, Allen WE, Bain J et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110δ. Cancer Res 2003; 63: 1667-1675.
73. Cornillet-Lefebvre P, Cuccuini W, Bardet V, Tamburini J, Gillot L, Ifrah N et al. Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110δ mutations. Leukemia 2006; 20: 374-376.
74. Bousquet M, Recher C, Queleen C, Demur C, Payrastre B, Brousset P. Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia. Br J Haematol 2005; 131: 411-413.
75. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004; 3: 1221-1224.
76. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006; 18: 77-82.
77. Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn JS, Ko YW et al. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol 2003; 122: 454-456.
78. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 2001; 276: 48627-48630.
79. Liu TC, Lin PM, Chang JG, Lee JP, Chen TP, Lin SF. Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol 2000; 63: 170-175.
80. Aggerholm A, Gronbaek K, Guldberg P, Hokland P. Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Eur J Haematol 2000; 65: 109-113.
81. Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet 1999; 8: 185-193.
82. Luo JM, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K et al. Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 2003; 17: 1-8.
83. Yamamoto M, Suzuki Y, Kihira H, Miwa H, Kita K, Nagao M et al. Expressions of four major protein Ser/Thr phosphatases in human primary leukemic cells. Leukemia 1999; 13: 595-600.
84. Scavelli C, Vacca A, Di Pietro G, Dammacco F, Ribatti D. Crosstalk between angiogenesis and lymphangiogenesis in tumor progression. Leukemia 2004; 18: 1054-1058.
85. Gutierrez NC, Lopez-Perez R, Hernandez JM, Isidro I, Gonzalez B, Delgado M et al. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 2005; 19: 402-409.
86. List AF, Glinsmann-Gibson B, Stadheim C, Meuillet EJ, Bellamy W, Powis G. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol 2004; 32: 526-535.
87. Wakabayashi M, Miwa H, Shikami M, Hiramatsu A, Ikai T, Tajima E et al. Autocrine pathway of angiopoietins-Tie2 system in AML cells: Association with phosphatidyl-inositol 3 kinase. Hematol J 2004; 5: 353-360.
88. Neri LM, Borgatti P, Tazzari PL, Bortul R, Cappellini A, Tabellini G et al. The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res 2003; 1: 234-246.
89. Estrov Z, Meir R, Barak Y, Zaizov R, Zadik Z. Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts. J Clin Oncol 1991; 9: 394-399.
90. Grimberg A. Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2003; 2: 630-635.
91. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene 2002; 21: 5673-5683.
92. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003; 9: 1158-1165.
93. De Toni F, Racaud-Sultan C, Chicanne G, Mas VM, Cariven C, Mesange F et al. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 2006, in press.
94. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 2005; 106: 4261-4268.
95. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004; 22: 4217-4226.
96. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11: 11-23.
97. Tamm I, Wagner M, Schmelz K. Decitabine activates specific caspases downstream of p73 in myeloid leukemia. Ann Hematol 2005; 84 (Suppl 13): 47-53.
98. Rizzo MG, Giombini E, Diverio D, Vignetti M, Sacchi A, Testa U et al. Analysis of p73 expression pattern in acute myeloid leukemias: Lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia 2004; 18: 1804-1809.
99. Olesen LH, Aggerholm A, Andersen BL, Nyvold CG, Guldberg P, Norgaard JM et al. Molecular typing of adult acute myeloid leukaemia: Significance of translocations, tandem duplications, methylation, and selective gene expression profiling. Br J Haematol 2005; 131: 457-467.
100. van Stijn A, van der Pol MA, Kok A, Bontje PM, Roemen GM, Beelen RH et al. Differences between the CD34+and CD34-blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica 2003; 88: 497-508.
101. Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M et al. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 2004; 112: 974-985.
102. Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C et al. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/ JNK. Blood 2005; 105: 1706-1716.
103. O'Gorman DM, McKenna SL, McGahon AJ, Cotter TG. Inhibition of PI3-kinase sensitises HL60 human leukaemia cells to both chemotherapeutic drug- and Fas-induced apoptosis by a JNK independent pathway. Leuk Res 2001; 25: 801-811.
104. Lunghi P, Tabilio A, Pinelli S, Valmadre G, Ridolo E, Albertini R et al. Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. Hematol J 2001; 2: 70-80.
105. Zhou BP, Hung MC. Novel targets of Akt, p21(Cipl/WAF1), and MDM2. Semin Oncol 2002; 29: 62-70.
106. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002; 27: 462-467.
107. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-3157.
108. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24: 7410-7425.
109. Arden KC, Biggs III WH. Regulation of the FoxO family of transcription factors by phosphatidylinositol-3 kinase-activated signaling. Arch Biochem Biophys 2002; 403: 292-298.
110. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: Mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004; 380: 297-309.
111. Cappellini A, Tabellini G, Zweyer M, Bortul R, Tazzari PL, Billi AM et al. The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression. Leukemia 2003; 17: 2157-2167.
112. Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn JS, Ko YW et al. Constitutive phosphorylation of FKHR transcription factor as a prognostic variable in acute myeloid leukemia. Leuk Res 2003; 27: 1159-1162.
113. Gupta P, Niehans GA, LeRoy SC, Gupta K, Morrison VA, Schultz C et al. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia 1999; 13: 44-53.
114. Lee JJ, Chung IJ, Park MR, Ryang DW, Park CS, Kim HJ. Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia. Leuk Res 2001; 25: 1067-1073.
115. Aggarwal BB. Nuclear factor-κB: The enemy within. Cancer Cell 2004; 6: 203-208.
116. Shishodia S, Aggarwal BB. Nuclear factor-kappaB activation: A question of life or death. J Biochem Mol Biol 2002; 35: 28-40.
117. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004; 18: 2195-2224.
118. Bortul R, Tazzari PL, Cappellini A, Tabellini G, Billi AM, Bareggi R et al. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIP(L) up-regulation. Leukemia 2003; 17: 379-389.
119. Tabellini G, Cappellini A, Tazzari PL, Fala F, Billi AM, Manzoli L et al. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 2005; 202: 623-634.
120. Baumgartner B, Weber M, Quirling M, Fischer C, Page S, Adam M et al. Increased IκB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia 2002; 16: 2062-2071.
121. Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P et al. Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005; 105: 804-811.
122. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512.
123. Min YH, Cheong JW, Kim JY, Eom JI, Lee ST, Hahn JS et al. Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res 2004; 64: 5225-5231.
124. Min YH, Cheong JW, Lee MH, Kim JY, Lee ST, Hahn JS et al. Elevated S-phase kinase-associated protein 2 protein expression in acute myelogenous leukemia: Its association with constitutive phosphorylation of phosphatase and tensin homologue protein and poor prognosis. Clin Cancer Res 2004; 10: 5123-5130.
125. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12: 3499-3511.
126. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000; 404: 782-787.
127. Seoane J, Le HV, Shen L, Anderson SA, Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004; 117: 211-223.
128. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 2002; 22: 2025-2036.
129. Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2002; 2: 81-91.
130. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 2002; 22: 7842-7852.
131. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337.
132. Fingar DC, Blenis J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23: 3151-3171.
133. Tokunaga C, Yoshino K, Yonezawa K. mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun 2004; 313: 443-446.
134. Martin DE, Soulard A, Hall MN. TOR regulates ribosomal protein gene expression via PKA and the Forkhead transcription factor FHL1. Cell 2004; 119: 969-979.
135. Giles FJ, Albitar M. Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 2005; 5: 653-661.
136. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002; 10: 151-162.
137. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003; 5: 578-581.
138. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8: 179-183.
139. Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006; 12: 679-689.
140. Hardt SE, Sadoshima J. Glycogen synthase kinase-3β: A novel regulator of cardiac hypertrophy and development. Circ Res 2002; 90: 1055-1063.
141. Prunier C, Hocevar BA, Howe PH. Wnt signaling: Physiology and pathology. Growth Factors 2004; 22: 141-150.
142. Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004; 24: 2890-2904.
143. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/β-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005; 24: 2410-2420.
144. Tickenbrock L, Schwable J, Wiedehage M, Steffen B, Sargin B, Choudhary C et al. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood 2005; 105: 3699-3706.
145. O'Gorman DM, McKenna SL, McGahon AJ, Knox KA, Cotter TG. Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia 2000; 14: 602-611.
146. Puccetti E, Ruthardt M. Acute promyelocytic leukemia: PML/RARα and the leukemic stem cell. Leukemia 2004; 18: 1169-1175.
147. Ramos AM, Fernandez C, Amran D, Sancho P, de Blas E, Aller P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 2005; 105: 4013-4020.
148. Tabellini G, Tazzari PL, Bortul R, Evangelisti C, Billi AM, Grafone T et al. Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. Br J Haematol 2005; 130: 716-725.
149. Sanz MA, Fenaux P, Lo Coco F. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005; 90: 1231-1235.
150. Bouralexis S, Findlay DM, Evdokiou A. Death to the bad guys: Targeting cancer via Apo2L/TRAIL. Apoptosis 2005; 10: 35-51.
151. Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia 2005; 19: 2195-2202.
152. Cappellini A, Mantovani I, Tazzari PL, Grafone T, Martinelli G, Cocco L et al. Application of flow cytometry to molecular medicine: Detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts. Int J Mol Med 2005; 16: 1041-1048.
153. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005; 90: 612-624.
154. Guo F, Sigua C, Tao J, Bali P, George P, Li Y et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004; 64: 2580-2589.
155. Kataoka T. The caspase-8 modulator c-FLIP. Crit Rev Immunol 2005; 25: 31-58.
156. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803.
157. Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M et al. Caspase-independent cell death in AML: Caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 2003; 102: 4179-4186.
158. Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W et al. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 2003; 17: 2081-2089.
159. Cai D, Wang Y, Ottmann OG, Barth PJ, Neubauer A, Burchert A. FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. Blood 2006; 107: 2094-2097.
160. Schmidt-Arras D, Schwable J, Bohmer FD, Serve H. Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr Pharm Des 2004; 10: 1867-1883.
161. Levis M. Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia. Curr Opin Hematol 2005; 12: 55-61.
162. Morgan MA, Ganser A, Reuter CW. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia 2003; 17: 1482-1498.
163. Moehler TM, Hillengass J, Goldschmidt H, Ho AD. Antiangiogenic therapy in hematologic malignancies. Curr Pharm Des 2004; 10: 1221-1234.
164. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J et al. In vivo antitumor activity of NVP-AEW541 - a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231-239.
165. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 2003; 4: 257-262.
166. Martelli AM, Tabellini G, Bortul R, Tazzari PL, Cappellini A, Billi AM et al. Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol Histopathol 2005; 20: 239-252.
167. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: Molecular target for cancer drug discovery. Oncogene 2005; 24: 7482-7492.
168. Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005; 4: 1349-1357.
169. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 2003; 170: 2647-2654.
170. Mora A, Komander D, van Aalten DM, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 2004; 15: 161-170.
171. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004; 3: 1001-1010.
172. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002; 21: 1727-1738.
173. Komander D, Kular GS, Bain J, Elliott M, Alessi DR, Van Aalten DM. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J 2003; 375: 255-262.
174. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006; 107: 2517-2524.
175. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003; 22: 6609-6620.
176. Gills JJ, Dennis PA. The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin Investig Drugs 2004; 13: 787-797.
177. Kumar CC, Madison V. AKT crystal structure and AKT-specific inhibitors. Oncogene 2005; 24: 7493-7501.
178. Castillo SS, Brognard J, Petukhov PA, Zhang C, Tsurutani J, Granville CA et al. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res 2004; 64: 2782-2792.
179. Meuillet EJ, Ihle N, Baker AF, Gard JM, Stamper C, Williams R et al. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 2004; 14: 513-527.
180. Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003; 17: 1794-1805.
181. Tabellini G, Tazzari PL, Bortul R, Billi AM, Conte R, Manzoli L et al. Novel 2′-substituted, 3′-decoy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway. Br J Haematol 2004; 126: 574-582.
182. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2: 1093-1103.
183. Chun KH, Kosmeder II JW, Sun S, Pezzuto JM, Lotan R, Hong WK et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 2003; 95: 291-302.
184. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005; 385: 399-408.
185. DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander KR et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 2005; 4: 271-279.
186. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005; 4: 977-986.
187. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004; 64: 4394-4399.
188. Shin I, Edl J, Biswas S, Lin PC, Mernaugh R, Arteaga CL. Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res 2005; 65: 2815-2824.
189. Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, Cappellini A et al. Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol 2005; 129: 677-686.
190. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005; 65: 2422-2432.
191. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, in press.
192. Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002; 38: 1615-1621.
193. Yang ZZ, Tschopp O, Baudry A, Dummler B, Hynx D, Hemmings BA. Physiological functions of protein kinase B/Akt. Biochem Soc Trans 2004; 32: 350-354.
194. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003; 15: 419-424.
195. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-410.
196. Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 2002; 16: 1535-1540.
197. George P, Bali P, Cohen P, Tao J, Guo F, Sigua C et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 2004; 64: 3645-3652.
198. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105: 1768-1776.
199. Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X et al. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. Leuk Res 2006; 30: 575-582.
200. Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005; 106: 318-327.
201. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005; 280: 40406-40416.
202. Dutcher JP. Mammalian target of rapamycin inhibition. Clin Cancer Res 2004; 10: 6382S-6387S.
203. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3: 371-377.
204. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105: 2527-2534.
205. Hahn M, Li W, Yu C, Rahmani M, Dent P, Grant S. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 2005; 4: 457-470.
206. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998; 91: 991-1000.
207. van Stijn A, Kok A, van der Pol MA, Feller N, Roemen GM, Westra AH et al. A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia. Leukemia 2003; 17: 780-786.
208. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P et al. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/ Akt-dependent process. Cancer Res 2003; 63: 1822-1833.
209. Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 2005; 19: 2153-2158.
210. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64: 3892-3899.
211. Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: A novel target for cancer therapy. Anticancer Drugs 2005; 16: 901-909.
212. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001; 12: 363-369.
213. Fisher TL, White MF. Signaling pathways: The benefits of good communication. Curr Biol 2004; 14: R1005-R1007.
214. Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: MTOR signalling goes back to the membrane. Trends Biochem Sci 2005; 30: 35-42.
215. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005; 4: 1533-1540.
216. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230.
217. Miller DS, Fricker G, Drewe J. p-Glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J Pharmacol Exp Ther 1997; 282: 440-444.
218. van der Kolk DM, de Vries EG, Noordhoek L, van den Berg E, van der Pol MA, Muller M et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 2001; 15: 1544-1553.
219. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
220. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002; 99: 16220-16225.
221. Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy. Cancer Lett 2004; 215: 129-140.
222. Kuo ML, Huang TS, Lin JK. Curcumin, an antioxidant and antitumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta 1996; 1317: 95-100.
223. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: Its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 2002; 23: 143-150.
224. Ito K, Nakazato T, Yamato K, Miyakawa Y, Yamada T, Hozumi N et al. Induction of apoptosis in leukemic cells by homovanillic acid derivative, capsaicin, through oxidative stress: Implication of phosphorylation of p53 at Ser-15 residue by reactive oxygen species. Cancer Res 2004; 64: 1071-1078.
225. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM et al. Resveratrol blocks interleukin-1β-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 2003; 102: 987-995.
226. Takada Y, Andreeff M, Aggarwal BB. Indole-3-carbinol suppresses NF-κB and IkappaBalpha kinase activation, causing inhibition of expression of NF-κB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 2005; 106: 641-649.
227. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-κ B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995; 270: 14255-14258.
228. Hansson A, Marin YE, Suh J, Rabson AB, Chen S, Huberman E et al. Enhancement of TPA-induced growth inhibition and apoptosis in myeloid leukemia cells by BAY 11-7082, an NF-kappaB inhibitor. Int J Oncol 2005; 27: 941-948.
229. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2006, in press.
230. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
231. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-3065.
232. Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F et al. NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006; 107: 1156-1165.
233. Nyakern M, Tazzari PL, Finelli C, Bosi C, Follo MY, Grafone T et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients Leukemia 2006; 20: 230-238.
234. Shishodia S, Aggarwal BB. Nuclear factor-κB: A friend or a foe in cancer? Biochem Pharmacol 2004; 68: 1071-1080.
235. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, Harding G et al. Transcription factor NF-κB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005; 25: 5404-5416.
236. Workman P. The opportunities and challenges of personalized genome-based molecular therapies for cancer: Targets, technologies, and molecular chaperones. Cancer Chemother Pharmacol 2003; 52 (Suppl 1): S45-S56.
237. Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001; 98: 2853-2855.
238. Tazzari PL, Cappellini A, Bortul R, Ricci F, Billi AM, Tabellini G et al. Flow cytometric detection of total and serine 473 phosphorylated Akt. J Cell Biochem 2002; 86: 704-715.
239. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: Monitoring single cell signaling events. Cytometry A 2003; 55: 61-70.
240. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004; 118: 217-228.
241. Krutzik PO, Hale MB, Nolan GP. Characterization of the murine immunological signaling network with phosphospecific flow cytometry. J Immunol 2005; 175: 2366-2373.
242. Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J et al. A phase I trial of perifosine (NSC 639966) on a loading dose/ maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004; 10: 7450-7456.
243. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001; 19: 2319-2333.
244. Geddis AE, Fox NE, Kaushansky K. Phosphatidylinositol 3-kinase is necessary but not sufficient for thrombopoietin-induced proliferation in engineered Mpl-bearing cell lines as well as in primary megakaryocytic progenitors. J Biol Chem 2001; 276: 34473-34479.
245. Myklebust JH, Blomhoff HK, Rusten LS, Stokke T, Smeland EB. Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells. Exp Hematol 2002; 30: 990-1000.
246. Lewis JL, Marley SB, Ojo M, Gordon MY. Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation in vitro. Exp Hematol 2004; 32: 36-44.
247. Young SM, Cambareri AC, Ashman LK. Role of c-KIT expression level and phosphatidylinositol 3-kinase activation in survival and proliferative responses of early myeloid cells. Cell Signal 2006; 18: 608-620.
248. Barnache S, Le Scolan E, Kosmider O, Denis N, Moreau-Gachelin F. Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene. Oncogene 2006; 25: 1420-1423.
249. Ghaffari S, Kitidis C, Zhao W, Marinkovic D, Fleming MD, Luo B et al. AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood 2006; 107: 1888-1891.
250. Zhao W, Kitidis C, Fleming MD, Lodish HF, Ghaffari S. Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/ AKT signaling pathway. Blood 2006; 107: 907-915.